Zacks Research Upgrades ICU Medical (NASDAQ:ICUI) to “Strong-Buy”

ICU Medical (NASDAQ:ICUI) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

A number of other brokerages have also weighed in on ICUI. Piper Sandler reduced their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Needham & Company LLC raised ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 27th. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. BTIG Research assumed coverage on shares of ICU Medical in a research note on Monday, June 15th. They issued a “buy” rating and a $170.00 price target on the stock. Finally, KeyCorp dropped their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Three analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $168.40.

ICU Medical Trading Down 0.9%

ICUI opened at $146.60 on Monday. The business has a fifty day moving average price of $132.26 and a 200 day moving average price of $138.42. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. ICU Medical has a 12 month low of $107.00 and a 12 month high of $160.29. The stock has a market capitalization of $3.66 billion, a price-to-earnings ratio of 79.24, a PEG ratio of 2.07 and a beta of 0.77.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. During the same quarter last year, the business posted $1.72 EPS. The business’s quarterly revenue was down 12.3% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Sell-side analysts expect that ICU Medical will post 6.5 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by corporate insiders.

Institutional Trading of ICU Medical

A number of hedge funds have recently added to or reduced their stakes in ICUI. AQR Capital Management LLC increased its holdings in shares of ICU Medical by 2.5% in the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after purchasing an additional 229 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in ICU Medical by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after buying an additional 560 shares during the last quarter. United Services Automobile Association acquired a new stake in shares of ICU Medical in the 1st quarter worth $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of ICU Medical by 32.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after acquiring an additional 16,680 shares during the period. Finally, Intech Investment Management LLC boosted its holdings in shares of ICU Medical by 38.6% in the first quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock valued at $1,658,000 after acquiring an additional 3,326 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.